Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
12.3(c) 12.36(c) 12.12(c) 12.22(c) 11.88 Last
5 553 1 816 38 550 16 568 30 838 Volume
0.00% +0.49% -1.94% +0.83% -2.78% Change
More quotes
Financials (CHF)
Sales 2019 75,8 M
EBIT 2019 -5,80 M
Net income 2019 -0,59 M
Finance 2019 15,0 M
Yield 2019 -
Sales 2020 28,5 M
EBIT 2020 -56,3 M
Net income 2020 -49,6 M
Finance 2020 42,0 M
Yield 2020 -
P/E ratio 2019 -231x
P/E ratio 2020 -4,94x
EV / Sales2019 1,59x
EV / Sales2020 3,29x
Capitalization 136 M
More Financials
Company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s... 
Sector
Pharmaceuticals
Calendar
10/17Presentation
More about the company
Latest news on SANTHERA PHARMACEUTICALS H
10/07Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with V..
GL
09/18SANTHERA PHARMACEUTICALS : to Present Long-Term Data with Puldysa in Duchenne Mu..
AQ
09/17Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Musc..
GL
09/10Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journ..
GL
09/03Santhera Announces Financial Results for the First Half-Year 2019
GL
08/28SANTHERA PHARMACEUTICALS : Announces Publication by ReveraGen of Positive Phase ..
AQ
08/27Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension S..
GL
08/12SANTHERA PHARMACEUTICALS : Announces Executive Management Change
AQ
08/09SANTHERA PHARMACEUTICALS : Announces Executive Management Change
AQ
08/05SANTHERA PHARMACEUTICALS : Announces Closing of Licensing Transaction with Chies..
AQ
08/02Santhera Announces Closing of Licensing Transaction with Chiesi Group for Rax..
GL
06/26SANTHERA PHARMACEUTICALS : EMA Validates Santhera's Marketing Authorization Appl..
AQ
06/25SANTHERA PHARMACEUTICALS : UK's MHRA renews EAMS Scientific Opinion for Santhera..
AQ
06/25SANTHERA PHARMACEUTICALS : EMA Validates Santhera's Marketing Authorization Appl..
PU
06/24SANTHERA PHARMACEUTICALS : UK's MHRA renews EAMS Scientific Opinion for Santhera..
PU
More news
News in other languages on SANTHERA PHARMACEUTICALS H
10/07SANTHERA PHARMACEUTICALS : gibt Präsentation durch ReveraGen von positiven 18-Mo..
10/07Santhera-Partner ReveraGen legt positive Daten zu Vamorolone bei DMD vor
09/17SANTHERA PHARMACEUTICALS : präsentiert Langzeitdaten mit Puldysa® (Idebenon) bei..
09/17Santhera kündigt Langzeitdaten zu Puldysa für verschiedene Fachkongresse an
09/10Santhera boucle une première étape clinique contre la fibrose kystique
More news
Analyst Recommendations on SANTHERA PHARMACEUTICALS H
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
05:25aTeva to donate over $15 billion worth of drugs in opioid settlement - source
RE
02:49aJOHNSON & JOHNSON : J&J Seeks $4 Billion Opioid Settlement
DJ
10/16DRUG FIRMS OFFER TO SETTLE U.S. OPIO : sources
RE
10/16JOHNSON & JOHNSON : J&J Offers $4 Billion Opioid Litigation Settlement
DJ
10/16Johnson & Johnson Shares Rise
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 2
Average target price 12,00  CHF
Last Close Price 12,22  CHF
Spread / Highest target -1,80%
Spread / Average Target -1,80%
Spread / Lowest Target -1,80%
EPS Revisions
Managers
NameTitle
Thomas Meier Chief Executive Officer & Director
Elmar J. Schnee Chairman
Christoph Rentsch Chief Financial Officer & IR Contact
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Martin Gertsch Vice Chairman
Sector and Competitors